Shattuck Labs Finalizes $75M Public Offering at $4.00/Share, Significant Dilution Expected
STTK has more than doubled off its 52-week low of $0.712 on light trading volume (0.4× avg).
Summary
Shattuck Labs has formalized a public offering of common stock and pre-funded warrants, raising up to $81.1 million at $4.00 per share, which will significantly dilute existing shareholders but provides essential capital for clinical development.
Key Events · Financing and Capital Events · STTK
-
Public Offering Finalized
Shattuck Labs is selling 10,879,376 shares of common stock and pre-funded warrants to purchase 7,870,624 shares, totaling 18,750,000 shares. This finalizes the terms of an offering previously reported as priced on June 10, 2026.
-
Pricing Details
The offering price is $4.00 per share of common stock and $3.9999 per pre-funded warrant. This is at a discount to the last reported sale price of $4.27 on June 9, 2026.
-
Capital Raised
The company expects to receive net proceeds of approximately $70.5 million, potentially increasing to $81.1 million if the underwriters fully exercise their option to purchase an additional 2,812,500 shares.
-
Significant Dilution
The offering could result in a dilution of 24.8% to 28.5% of existing shares outstanding, based on 75.6 million shares outstanding as of March 31, 2026.
Analysis · STTK · Life Sciences
This 424B5 prospectus supplement formalizes the terms of a public offering, previously reported as priced on June 10, 2026, and finalized on June 11, 2026. The offering will raise approximately $70.5 million (or up to $81.1 million if the underwriters' option is fully exercised) through the sale of common stock and pre-funded warrants. The offering price of $4.00 per share is at a discount to the recent market price. This capital raise is highly dilutive, potentially increasing outstanding shares by 24.8% to 28.5%, but provides crucial funding for ongoing clinical trials and general corporate purposes, extending the company's cash runway.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 34.8% of the 1152 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, STTK was trading at $4.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $319M. The 52-week trading range was $0.71 to $8.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.